LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Home・Stock List・Incyte Corp

Incyte Corp

Open

SectorHealthcare

96.95 -0.09

Buy Sell

Overview

Share price change

24h

Current

Min

96.18

Max

97.81

Key metrics
By Trading Economics
Income	4.1M 303M
Sales	-234M 1.3B
P/E Sector Avg	13.723 50.102
EPS	1.81
Profit margin	23.834
Employees	2,844
EBITDA	-47M 368M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+11.25% upside

Dividends
By Dow Jones
Next Earnings	28 Jul 2026

Market Stats
By TradingEconomics
Market Cap	362M 19B
Previous open	97.04
Previous close	96.95

News Sentiment

By Acuity

58%

42%

277 / 344 Healthcare

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

28 May 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 May 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 May 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 May 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 May 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 May 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 May 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 May 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 May 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 May 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 May 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 May 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 May 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 May 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 May 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 May 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 May 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 May 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 May 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 May 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 May 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 May 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 May 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 May 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 May 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 May 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 May 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

11.25% upside

12 Months Forecast

Average 108.29 USD 11.25%

High 135 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Sentiment

By Acuity

277 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation